Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €5.26 EUR
Change Today +0.03 / 0.57%
Volume 18.3K
STNT On Other Exchanges
EN Paris
As of 11:35 AM 11/26/15 All times are local (Market data is delayed by at least 15 minutes).

stentys (STNT) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/29/15 - €7.09
52 Week Low
12/16/14 - €4.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for STENTYS (STNT)

Related News

No related news articles were found.

stentys (STNT) Related Businessweek News

No Related Businessweek News Found

stentys (STNT) Details

STENTYS Société anonyme, a medical technology company, engages in the development and commercialization of self-apposing stents to treat acute myocardial infarction, bifurcation lesions, and other complex coronary diseases in European countries. The company’s Self-Apposing stent technology consists of a self-expanding stent platform to treat coronary arteries with ambiguous vessel diameters or with areas of vessel diameter fluctuations. Its products portfolio includes the Self-Apposing STENTYS bare metal stents and DES (P) stents; and the STENTYS AC aspiration catheter, a deliverable thrombectomy device for thrombus-containing lesions. The company serves interventional cardiologists in Europe, the Middle East, and Asia. STENTYS Société anonyme was founded in 2006 and is headquartered in Paris, France.

39 Employees
Last Reported Date: 04/14/15
Founded in 2006

stentys (STNT) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: €219.9K
Compensation as of Fiscal Year 2014.

stentys (STNT) Key Developments

STENTYS Reports Revenue Results for the Third Quarter and Nine Months of 2015

STENTYS reported revenue results for the third quarter and nine months of 2015. For the quarter, the company reported revenues of €1,615,600 against €876,500 a year ago, an increase of 84.3%. For the nine months, the company's revenues were up 50%, to €4,221,600 against €2,812,400 a year ago, an increase of 50.1%.

STENTYS to Present Follow-Up Imaging Data from APPOSITION IV Study at TCT Conference in San Francisco

STENTYS announced that three-year follow-up imaging data from the STENTYS arm of the APPOSITION IV clinical study confirms the long-term performance of the sirolimus-eluting Self-Apposing stent. The data will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco, CA. The data were obtained by Quantitative Coronary Angiography (QCA) and Optical Coherence Tomography (OCT) from a group of patients that were examined three years post-treatment for ST-elevation Myocardial Infarction with the STENTYS stent. The in-stent Late Lumen Loss was 0.08mm (±0.43), while the rate of well-apposed struts was 99.3% and the rate of strut covered by tissue was 99.7%. APPOSITION IV is a prospective, randomized, four-arm, multi-center study designed to compare the STENTYS Sirolimus eluting stent (90 patients) with Medtronic Resolute® (62 patients) in the treatment of ST-elevation Myocardial Infarction. Patients were followed up at either 4 months (63 patients) or 9 months (89 patients). Stent apposition was statistically better in the STENTYS group than the balloon-expandable group at 4 months, and a greater percentage of STENTYS stents were fully covered by vessel tissue (33% vs 4%, p=0.02), a marker for healing. At 9 months, the STENTYS SES showed no reduction in artery lumen diameter (Late Lumen Loss of 0.04mm ±0.43 under QCA) with a near perfect arterial healing (99% covered struts at 9 months under OCT).

STENTYS Reports Earnings Results for the Six Months Ended June 30, 2015

STENTYS announced earnings results for the six months ended June 30, 2015. For the period, the company reported revenues of €2,606,000 against €1,936,000 a year ago. Operating loss was €5,449,000 against €13,339,000 a year ago. Net loss was €5,421,000 against €13,190,000 a year ago, driven by a decrease in operating costs and the termination of the APPOSITION V clinical trial.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STNT:FP €5.26 EUR +0.03

STNT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $45.41 USD -0.04
Boston Scientific Corp $18.38 USD +0.06
InspireMD Inc $0.80 USD 0.00
Johnson & Johnson $101.96 USD -0.08
Medtronic PLC $76.56 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation STNT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.9x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.6x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact STENTYS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at